Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
![]() CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Great news to share from the CCTG IC8 trial team! The study already has 6 sites currently participating with 29 patients accrued. Congrats to all of the trial teams at: Read More |
CCTG trials BR28 and BL12 have been permanently closed.
Read More
|
The CCTG Pharmacy Network is actively seeking pharmacy representation for the Genitourinary Disease Site Committee and the Steering Group - Quebec. Read More |
CCTG SC24 practice changing trial results presented at the ASTRO 2020 meetingPublished: November 04, 2020Category: News Lead author Dr. Arjun Sahgal, deputy chief of radiation oncology at the Sunnybrook Health Sciences Centre of the University of Toronto, presented the findings from the CCTG SC24 at the American Society for Radiation Oncology (ASTRO) Annual Meeting last week. This randomized phase II/III trial is the first to show that stereotactic body radiation therapy is superior to conventional radiation treatments in alleviating pain from spinal metastases.
Read More |
The Canadian Cancer Society developing a new Research StrategyPublished: November 04, 2020Category: News The Canadian Cancer Society (CCS) is seeking your input on the development of a new CCS Research Strategy. |
Call for Nominations: Canadian Cancer Society Awards for ExcellencePublished: November 04, 2020Category: News The Canadian Cancer Society Awards for Excellence in Cancer Research recognize individuals who have made, and are making, valuable contributions to the cancer research ecosystem in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community. There are two new awards this year find out more here. Read More |
Publication for CCTG CO17
Loree JM, Dowers A, Tu D, Jonker D, Edelstein DL, Quinn H, Holtrup F, Price T, Zalcberg JR, Moore MJ, Karapetis CS, Callaghan CJ, Waring P, Kennecke HF, Hamilton SR, Kopetz S. Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial (ONLINE). Clin Cancer Res clincanres, 2020.
Read More |
Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competitionPublished: October 21, 2020Category: News Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition. Read More |